Saturday, November 21, 2026

Subscribe

EconomyEdition South AfricaSouth Africa

FuturePHARMA seeks to bridge research and industry amid South Africa’s medicine imports

South Africa launches FuturePHARMA, a platform designed to advance pharmaceutical innovations towards production. The project tackles heavy reliance on imported active ingredients, but its impact will depend on the products actually developed and manufactured.

A logistics worker unloads boxes of pharmaceutical products beside buses at a station in Tshwane, South Africa.

A promising laboratory discovery does not automatically become a medicine available in pharmacies. In South Africa, new public infrastructure aims to bridge part of this gap and reduce reliance on imported pharmaceutical ingredients.

From laboratory to manufacturing: strengthening the missing link

The Council for Scientific and Industrial Research (CSIR) inaugurated FuturePHARMA on 7 October 2026, a research and manufacturing platform located in Tshwane, Gauteng province. President Cyril Ramaphosa attended the launch. The centre is intended to help take healthcare products from research through trials and scale-up, and ultimately into production.

FuturePHARMA will provide specialised equipment and expertise. Universities, researchers, start-ups and industry players will be able to develop pharmaceutical processes there and prepare products for more advanced stages. Shared access to these facilities can be important: building state-of-the-art equipment independently is a cost that many small teams would struggle to bear.

The CSIR describes the site as open infrastructure, designed in particular to develop active pharmaceutical ingredients. An active ingredient is the substance that produces a medicine’s therapeutic effect. The centre is also intended to support technology transfer, the process of adapting a laboratory method to the demands of larger-scale manufacturing.

At the launch, Ramaphosa described the facility as having the potential to “change the game” and linked the project to lessons from the Covid-19 pandemic. Disruptions to supply chains had shown that a country able to formulate medicines can remain vulnerable if it relies on external suppliers for their essential components.

An existing industry, but upstream dependence

South Africa already has a pharmaceutical sector and local formulation activities. But manufacturing a finished medicine is not the same as producing the substances that go into it. According to information provided by the CSIR and reported by the public news agency SAnews, around 98% of the active ingredients used in the country are imported. This proportion highlights the importance of the upstream link in the production chain.

This dependence exposes manufacturers to logistical delays, price changes and currency fluctuations. It does not mean imports can disappear quickly: some ingredients require specific technologies, expertise and production volumes. FuturePHARMA therefore aims to strengthen development and scale-up capabilities, without by itself guaranteeing full self-sufficiency or cheaper medicines.

The centre is also operating in a context where moving from research to commercialisation remains complex. A product must pass quality control, clinical evaluation and regulatory approval before reaching patients. Access to specialised equipment can facilitate this process, but it does not replace the necessary trials, decisions by health authorities or industrial investment.

For researchers and small businesses, the challenge is to be able to test and refine their processes without having to own all the facilities. For industry players, the potential benefit lies in access to expertise and technologies. For patients, the impact will depend above all on the ability to turn projects into approved, available and affordable products.

A South African and regional issue

The issue extends beyond South Africa’s borders. Southern Africa is organised around the Southern African Development Community (SADC), which brings together states in the region to promote economic cooperation. More widely distributed capabilities could help diversify regional supplies, provided countries can coordinate their standards, procurement and needs.

Across the continent, dependence remains high. Africa CDC says more than 95% of the active ingredients consumed in Africa are imported. The organisation also estimates that the continent imports more than 70% of the medicines it uses. These figures describe a shared challenge, but industrial capabilities, healthcare needs and priorities differ from one country to another.

Continental policy aims to increase local production. In 2026, a declaration adopted by African leaders and ministers reaffirmed the goal of meeting at least 60% of the continent’s needs for health products locally by 2040. Achieving this requires more than building facilities: it calls for sustainable financing, predictable demand, compatible quality standards and partnerships between African manufacturers.

FuturePHARMA forms part of this ambition, but its reach will depend on tangible results: the number of projects supported, products reaching trials, partnerships established and processes transferred to production. The CSIR plans to collaborate with African institutions and companies. Their implementation will show whether the platform becomes a tool for regional cooperation or remains primarily at the service of the domestic market.

The 7 October launch therefore marks an institutional milestone, not the culmination of a new industry. For South Africa, whose capital is Pretoria, the challenge will be to connect public research, industry, regulation and health procurement. For SADC and the continent, the complementary challenge is to build capabilities that reinforce one another, rather than replicate isolated production chains.

Automatic translation. Original French version

News quiz

Edition South AfricaSouth Africa: the news quiz for 13–15 November

5 questions